Climate Change Data

BIOSENIC SA

Climate Impact & Sustainability Data (2021, 2022, 2023, 2024-04)

Reporting Period: 2021

Environmental Metrics

ESG Focus Areas

  • Governance
  • Sustainability

Governance Achievements

  • Implemented a remuneration policy compliant with the new law of 28 April 2020 and the Belgian Corporate Governance Code 2020.
  • Established a Nomination and Remuneration Committee (RemCo) to oversee executive and non-executive director compensation.

Climate Goals & Targets

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: Belgian Corporate Governance Code 2020

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Not disclosed

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Not disclosed
Mitigation Strategies
  • Not disclosed

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed

Reporting Period: 2023

Environmental Metrics

Climate Goals & Targets

Environmental Challenges

  • High and unmanaged cost structure inherited from Bone Therapeutics.
  • Poor management of ALLOB and JTA projects leading to clinical failures.
  • Questionable reverse merger with Bone Therapeutics.
  • Difficulty in raising funds due to existing debt.
  • Abandonment of ALLOB and JTA applications due to clinical failures.
Mitigation Strategies
  • Cost reduction efforts.
  • Focus on the most promising clinical trials (Arscimed, ArsciCor, ArsciCop).
  • Securing funding from TrialCap Pte. Ltd. (8M EUR loan and 800K EUR equity).
  • Negotiating debt restructuring with creditors (BEI, Patronale, Monument).
  • Creating an Australian subsidiary to leverage Australian research tax credits.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Period: 2024-04

Environmental Metrics

Climate Goals & Targets

Medium-term Goals:
  • Obtain marketing authorization by the end of 2028.
Short-term Goals:
  • Start Phase III cGvHD clinical trial.

Environmental Challenges

  • High and unmanaged cost structure inherited from Bone Therapeutics.
  • Poor management of ALLOB and JTA projects leading to clinical failures.
  • Questionable reverse merger.
  • Difficulty in raising funds due to existing debt.
  • Abandonment of ALLOB and JTA applications due to clinical failures.
Mitigation Strategies
  • Cost reduction efforts.
  • Focus on promising clinical trials for Arscimed, ArsciCor, and ArsciCop.
  • Securing funding from TrialCap Pte. Ltd. (8M EUR loan and 800K EUR equity).
  • Negotiating debt restructuring with creditors (BEI, Patronale, Monument).
  • Creating an Australian subsidiary to leverage Australian research tax credits.

Supply Chain Management

Climate-Related Risks & Opportunities